Clinicians have slammed the Cochrane Review, highlighting the irresponsible nature of the review and its clinical flaws. In the media statement the Clinicians reaffirmed their support for the new generation of hepatitis C therapies, and are urging people to not be swayed by the flawed report.
The Cochrane Review suggests the Direct Acting Antiviral’s used to treat Chronic Hepatitis C could be ‘clinically ineffective’. In response, the Gastroenterological Society of Australia stated: “As someone who has dedicated my career to treating viral hepatitis, I am worried that misinformation stemming from this report may sway doctors away from prescribing DAAs and discourage patients from seeking and continuing treatment.”Statement: https://www.gesa.org.au/public/13/system/newsAttachments/GESA_Media_Release_Cochrane_15June2017.pdf
CEO of Hepatitis Australia, Helen Tyrrell, has released the statement: “Hepatitis C affects over 71 million people globally and kills around 400,000 people per year – the Cochrane Collaborators have clear social responsibility to make sure their reporting is both accurate and of a high standard.
My personal view of the Cochrane Collaboration has been shattered. There is collective and loud criticism coming from clinicians around the world which points to serious flaws and biases in their analysis of the value of treatment with the hepatitis C DAAs.
Our clear message to people who have been treated with the DAAs or are considering treatment is to be reassured that all the leading Australian experts we know are united in rejecting the Cochrane report and confirming that treatments which cure hepatitis C reduce the risk of liver cancer & liver failure. The hepatitis C cures are saving lives and improving the quality of lives.
New medicines in Australia don’t get listed on the PBS without a rigorous process of assessing costs, benefits and safety aspects. The Australian government have invested $1b in these cures which have absolutely revolutionised hepatitis C treatment and put us on a path to elimination of hepatitis C as a public health concern by 2030.”